Home › Targets › PSMA
PSMA (7 companies · 19 programs)
Companies with an active program directed at PSMA.
- TLX592-Tx — Prostate Cancer Phase 1
- lutetium (Lu177) rosopatamab tetraxetan — Prostate Cancer Phase 3
- 177Lu-DOTA-HYNIC-panPSMA — Prostate Cancer Phase 2
- RHN001-Tx — Prostate Cancer Phase 1
- RHN001-Dx — Prostate Cancer Phase 1
- Illuccix — Prostate Cancer Approved
- Gozellix — Prostate Cancer Approved
- TLX593-Px — Prostate Cancer
- TLX597-Tx — Metastatic Hormone-Sensitive Prostate Cancer Phase 2
- JANX007 — Metastatic Castration-Resistant Prostate Cancer Phase 1
- JANX013 — Metastatic Castration-Resistant Prostate Cancer Phase 1
- JANX014 — Metastatic Castration-Resistant Prostate Cancer Phase 1
- APVO442 — Prostate Cancer Preclinical
- APVO452 — Prostate Cancer Preclinical
- VIR-5500 — Metastatic Castration-Resistant Prostate Cancer Phase 1
- VIR-5500 — Metastatic Hormone-Sensitive Prostate Cancer Phase 1
- ADCT-241 — Prostate Cancer Preclinical
- ADI-212 — Metastatic Castration-Resistant Prostate Cancer Preclinical
- JNJ-9401 — Metastatic Castration-Resistant Prostate Cancer Phase 1
